Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Characterization and evaluation of a modified local lymph node assay using ATP content as a non-radio isotopic endpoint.

Idehara K, Yamagishi G, Yamashita K, Ito M.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):1-10. doi: 10.1016/j.vascn.2008.03.003. Epub 2008 Mar 26.

PMID:
18462956
2.

Interlaboratory validation of the modified murine local lymph node assay based on adenosine triphosphate measurement.

Omori T, Idehara K, Kojima H, Sozu T, Arima K, Goto H, Hanada T, Ikarashi Y, Inoda T, Kanazawa Y, Kosaka T, Maki E, Morimoto T, Shinoda S, Shinoda N, Takeyoshi M, Tanaka M, Uratani M, Usami M, Yamanaka A, Yoneda T, Yoshimura I, Yuasa A.

J Pharmacol Toxicol Methods. 2008 Jul-Aug;58(1):11-26. doi: 10.1016/j.vascn.2008.05.001. Epub 2008 May 21.

PMID:
18593646
3.

Local lymph node assay (LLNA) for detection of sensitization capacity of chemicals.

Gerberick GF, Ryan CA, Dearman RJ, Kimber I.

Methods. 2007 Jan;41(1):54-60. Review.

PMID:
16938465
4.

Application of BALB/c mouse in the local lymph node assay:BrdU-ELISA for the prediction of the skin sensitizing potential of chemicals.

Hou F, Xing C, Li B, Cheng J, Chen W, Zhang M.

J Pharmacol Toxicol Methods. 2015 Mar-Apr;72:53-8. doi: 10.1016/j.vascn.2015.01.001. Epub 2015 Jan 16.

PMID:
25600862
5.

Inter-laboratory validation of the modified murine local lymph node assay based on 5-bromo-2'-deoxyuridine incorporation.

Kojima H, Takeyoshi M, Sozu T, Awogi T, Arima K, Idehara K, Ikarashi Y, Kanazawa Y, Maki E, Omori T, Yuasa A, Yoshimura I.

J Appl Toxicol. 2011 Jan;31(1):63-74. doi: 10.1002/jat.1567.

PMID:
20677212
6.
8.

Advantage of using CBA/N strain mice in a non-radioisotopic modification of the local lymph node assay.

Takeyoshi M, Noda S, Yamasaki K, Kimber I.

J Appl Toxicol. 2006 Jan-Feb;26(1):5-9.

PMID:
16217858
9.
10.
11.

Gene expression profiles in auricle skin as a possible additional endpoint for determination of sensitizers: A multi-endpoint evaluation of the local lymph node assay.

Tsuchiyama H, Maeda A, Nakajima M, Kitsukawa M, Takahashi K, Miyoshi T, Mutsuga M, Asaoka Y, Miyamoto Y, Oshida K.

Toxicol Lett. 2017 Oct 5;280:133-141. doi: 10.1016/j.toxlet.2017.08.009. Epub 2017 Aug 18.

PMID:
28826779
12.

ICCVAM evaluation of the murine local lymph node assay. Conclusions and recommendations of an independent scientific peer review panel.

Dean JH, Twerdok LE, Tice RR, Sailstad DM, Hattan DG, Stokes WS.

Regul Toxicol Pharmacol. 2001 Dec;34(3):258-73.

PMID:
11754530
13.
14.

Use of the local lymph node assay in the evaluation of the sensitizing potential of pharmaceutical process intermediates.

Durand G, de Burlet G, Virat M, Nauman BD.

Contact Dermatitis. 2003 Sep;49(3):148-54.

PMID:
14678211
15.

Assessment of the skin sensitization potency of eugenol and its dimers using a non-radioisotopic modification of the local lymph node assay.

Takeyoshi M, Noda S, Yamazaki S, Kakishima H, Yamasaki K, Kimber I.

J Appl Toxicol. 2004 Jan-Feb;24(1):77-81.

PMID:
14745850
16.

The impact of vehicle on the relative potency of skin-sensitizing chemicals in the local lymph node assay.

Jowsey IR, Clapp CJ, Safford B, Gibbons BT, Basketter DA.

Cutan Ocul Toxicol. 2008;27(2):67-75. doi: 10.1080/15569520801904655.

PMID:
18568891
17.
19.

Comparison of BALB/c and CBA/J mice for the local lymph node assay using bromodeoxyuridine with flow cytometry (LLNA: BrdU-FCM).

Lee YS, Yi JS, Seo SJ, Kim JH, Jung MS, Seo IK, Ahn I, Ko K, Kim TS, Lim KM, Sohn S.

Regul Toxicol Pharmacol. 2017 Feb;83:13-22. doi: 10.1016/j.yrtph.2016.10.021. Epub 2016 Nov 2.

PMID:
27816673
20.

Skin sensitization testing in potency and risk assessment.

Kimber I, Basketter DA, Berthold K, Butler M, Garrigue JL, Lea L, Newsome C, Roggeband R, Steiling W, Stropp G, Waterman S, Wiemann C.

Toxicol Sci. 2001 Feb;59(2):198-208. Review.

PMID:
11158712

Supplemental Content

Support Center